SOHO 2025 | How the role of alloSCT has evolved in ALL with the introduction of novel agents
Alexandra Gomez-Arteaga, MD, Weill Cornell Medicine, New York, NY, briefly discusses how the role of allogeneic stem cell transplantation (alloSCT) has evolved in the treatment of acute lymphoblastic leukemia (ALL), highlighting the impact of novel therapies such as bispecific antibodies and CAR T-cells. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think it’s going to be changing year by year. So if we talk at 2025, we might have an answer that is not this good answer in 2026. I think the field is moving very rapidly. The most important example is ALL. I think ALL used to be the only curative option for high-risk ALL used to be transplant and now we have bispecifics and CAR-T and inotuzumab and then we have a very very very good ways of measuring residual disease so if you ask leukemia doctors when we transplant ALL they say almost never...
I think it’s going to be changing year by year. So if we talk at 2025, we might have an answer that is not this good answer in 2026. I think the field is moving very rapidly. The most important example is ALL. I think ALL used to be the only curative option for high-risk ALL used to be transplant and now we have bispecifics and CAR-T and inotuzumab and then we have a very very very good ways of measuring residual disease so if you ask leukemia doctors when we transplant ALL they say almost never. I still feel and I still we still transplant ALL and the way that we transplant ALL is because we have redefined our risk which is not only high-risk disease by very high-risk genomic profiles and also MRD dynamics and how good they get there. So I hope one day in the future we’ll not need transplant at all. Maybe that’s hopefully that would like it or we can make transplants so good and safe that the transplant related mortality and the chronic GvHD goes to almost nothing. Then absolutely. But the field is going to be evolving as we get better ways to treat diseases and better ways to monitor and decide who does not meet the toxicity. But up until that happens, transplant is still a very important option for patients that have high-risk disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
